Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930085 | 0.86 | — | — | |
| SCHEMBL16919248 | 0.82 | ALDH1A1 (0.33) | CYP19A1 | |
| SCHEMBL22959617 | 0.82 | — | — | |
| SCHEMBL10202604 | 0.82 | — | — | |
| SCHEMBL21933618 | 0.82 | — | — | |
| SCHEMBL21288010 | 0.81 | THRA (0.38) | — | |
| SCHEMBL19407087 | 0.79 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL19407060 | 0.79 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL16549318 | 0.79 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL15784784 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9957220-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2017-10-19 | — | — | US | disclosed |
| US-9701616-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9643911-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160368854-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9394227-B1 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2016-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368854-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
| US-20160368855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | CYP19A1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.